

# Maria G Tektonidou

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8252688/maria-g-tektonidou-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182  
papers

9,059  
citations

42  
h-index

93  
g-index

206  
ext. papers

11,901  
ext. citations

5.6  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
182	Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations.. <i>Endocrine</i> , <b>2022</b> , 75, 317	4	0
181	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	6
180	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases.. <i>RMD Open</i> , <b>2022</b> , 8,	5.9	6
179	Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis.. <i>Journal of Autoimmunity</i> , <b>2022</b> , 128, 102813	15.5	6
178	An Update on Antiphospholipid Syndrome.. <i>Current Rheumatology Reports</i> , <b>2022</b> , 23, 84	4.9	1
177	New Insights Into an Overlooked Entity: Long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 809533	4.9	
176	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40 Suppl 134, 93-102	2.2	1
175	All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	5
174	COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. <i>Rheumatology International</i> , <b>2021</b> , 42, 31	3.6	9
173	The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the RGO-UPP study. <i>Quality of Life Research</i> , <b>2021</b> , 1	3.7	0
172	Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. <i>Journal of Autoimmunity</i> , <b>2021</b> , 125, 102755	15.5	0
171	Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3-year prospective study. <i>Rheumatology</i> , <b>2021</b> ,	3.9	1
170	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	11
169	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> , 28, 346-352	3.9	4
168	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1490-1504	4.7	13
167	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. <i>Rheumatology</i> , <b>2021</b> , 60, 2976-2978	3.9	1
166	Growth Differentiation Factor 15 (GDF-15) as potential cardiovascular risk biomarker in Antiphospholipid Syndrome. <i>Rheumatology</i> , <b>2021</b> ,	3.9	4

165	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. <i>Rheumatology International</i> , <b>2021</b> , 41, 895-902	3.6	5
164	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 45	4.9	3
163	Adrenocortical dysfunction in rheumatoid arthritis: Narrative review and future directions. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , e13635	4.6	2
162	Psoriasis as an adverse reaction to biologic agents beyond anti-TNF- $\alpha$ therapy. <i>European Journal of Dermatology</i> , <b>2021</b> , 31, 307-317	0.8	3
161	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. <i>RMD Open</i> , <b>2021</b> , 7,	5.9	4
160	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	3
159	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , <b>2021</b> , 60, 170-178	3.9	7
158	Vasculitis beyond aortitis in IgG4-related disease (IgG4-RD): case report and review of the literature. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1167-1173	3.9	4
157	Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome. <i>Rheumatology</i> , <b>2021</b> , 60, 1669-1675	3.9	2
156	Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 2559-2568	3.9	0
155	Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 2223-2230	3.9	0
154	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 541-547	4.1	4
153	Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS). <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab029	1.1	0
152	Response to: Correspondence on EULAR recommendations for the management of antiphospholipid syndrome in adults by Gao and Qin. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	0
151	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
150	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , <b>2021</b> , 229, 108765	9	6
149	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 131, 29-33	2.2	
148	Outcomes of conventionally-treated systemic sclerosis patients eligible for autologous haematopoietic stem cell transplantation. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 29-33	2.2	0

147	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. <i>Lupus</i> , <b>2021</b> , 9612033211062523	2.6	3
146	Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	1
145	Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , <b>2020</b> , 11, 8	3.7	10
144	B-cell oligoclonal expansions in renal tissue of patients with immune-mediated glomerular disease. <i>Clinical Immunology</i> , <b>2020</b> , 217, 108488	9	3
143	The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	11
142	Underperformance of clinical risk scores in identifying vascular ultrasound-based high cardiovascular risk in systemic lupus erythematosus. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 2047487320906650	3.9	10
141	Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. <i>Rheumatology International</i> , <b>2020</b> , 40, 1361-1368	3.6	1
140	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102491	13.6	38
139	Combined Brain-Heart Magnetic Resonance Imaging in Autoimmune Rheumatic Disease Patients with Cardiac Symptoms: Hypothesis Generating Insights from a Cross-sectional Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
138	Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 6151-6157	15.9	307
137	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , <b>2020</b> , 31, 288-294	1.4	6
136	Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102329	15.5	24
135	Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 304-307	2.4	12
134	Response to: Correspondence on EULAR recommendations for the management of antiphospholipid syndrome in adults Pby Zhou. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	2
133	Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	2
132	Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20949088	3.8	1
131	Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20937132	3.8	1
130	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	13

129	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , <b>2020</b> , 10, 16648	4.9	1
128	Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. <i>Rheumatology</i> , <b>2020</b> , 59, v29-v38	3.9	21
127	Management of Non-criteria Manifestations in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 51	4.9	8
126	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , <b>2020</b> , 961203320940776	2.6	12
125	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
124	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , <b>2020</b> , 29, 1571-1593	2.6	27
123	Response to: Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus by Chatzidionysiou P, et al. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
122	Myocardial Involvement in Rheumatic Disorders. <i>Current Heart Failure Reports</i> , <b>2020</b> , 17, 171-180	2.8	3
121	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20976975	3.8	9
120	Joint microwave radiometry for inflammatory arthritis assessment. <i>Rheumatology</i> , <b>2020</b> , 59, 839-844	3.9	9
119	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	30
118	Differential performance of nailfold video capillaroscopic parameters in the diagnosis and prognosis of systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 125, 29-39	2.2	
117	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , <b>2019</b> , 175, 32-36	8.2	12
116	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1079-1089	2.4	45
115	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>RMD Open</i> , <b>2019</b> , 5, e000924	5.9	35
114	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1296-1304	2.4	312
113	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 464-468	5.3	38
112	Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. <i>Rheumatology</i> , <b>2019</b> , 58, 1794-1801	3.9	6

111	Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 487	8.4	22
110	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 125-132	3.9	26
109	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
108	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 2069-2080	15.4	4
107	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
106	Type I interferon gene expression in antiphospholipid syndrome: Pathogenetic, clinical and therapeutic implications. <i>Journal of Autoimmunity</i> , <b>2019</b> , 104, 102311	15.5	14
105	Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	8
104	Independent association of low IFN $\gamma$ gene expression and type I IFN score/IFN $\gamma$ ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. <i>Clinical Immunology</i> , <b>2019</b> , 209, 108265	9	7
103	Does seronegative obstetric APS exist? "pro" and "cons". <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102407	13.6	12
102	Guideline: EULAR provided recommendations for thrombotic and obstetric antiphospholipid syndrome. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, JC26	8	1
101	JAK inhibitors: promising for a wider spectrum of autoimmune diseases?. <i>Lancet, The</i> , <b>2019</b> , 394, 2047-2048	14.8	3
100	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 134-141	4.7	23
99	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2019</b> , 126, 656-661	3.7	16
98	The Second Greek-Israeli Symposium on Autoimmunity and Rheumatology: Success Through Synergy. <i>Israel Medical Association Journal</i> , <b>2019</b> , 21, 292-297	0.9	
97	Mechanics of early ventricular impairment in systemic sclerosis and the effects of peripheral arterial haemodynamics. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 119, 57-62	2.2	
96	Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 467-474	5.3	39
95	The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. <i>Rheumatology</i> , <b>2018</b> , 57, 1264-1270	3.9	40
94	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 883-889	5.3	17

93	Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus. <i>Lupus</i> , <b>2018</b> , 27, 564-571	2.6	27
92	Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1181	8.4	28
91	Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. <i>Rheumatology</i> , <b>2018</b> , 57, 2158-2166	3.9	13
90	Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. <i>Autoimmunity Reviews</i> , <b>2018</b> , 17, 816-820	13.6	23
89	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , <b>2018</b> , 29, 27-37	1.4	6
88	Stress perfusion Cardiac Magnetic Resonance in Patients with Antiphospholipid Syndrome. <i>Mediterranean Journal of Rheumatology</i> , <b>2018</b> , 29, 99-102	1.4	1
87	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000793	9.3	42
86	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , <b>2018</b> , 27, 399-406	2.6	39
85	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , <b>2018</b> , 4, e000785	5.9	21
84	Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 267	5.7	16
83	B-cell activating factor and related genetic variants in lupus related atherosclerosis. <i>Journal of Autoimmunity</i> , <b>2018</b> , 92, 87-92	15.5	32
82	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 476-485	2.4	375
81	Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 308-312	13.6	63
80	Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 626-630	4.1	
79	Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. <i>Rheumatology International</i> , <b>2017</b> , 37, 1249-1255	3.6	42
78	Retinal vascular calibers in contemporary patients with chronic systemic inflammatory diseases: The Greek REtinal Microcirculation (GREM) study. <i>Artery Research</i> , <b>2017</b> , 18, 1	2.2	4
77	Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases. <i>International Journal of Cardiology</i> , <b>2017</b> , 236, 151-156	3.2	34
76	Reply. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1705	9.5	2

75	Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2380-2385	9.5	20
74	Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 2009-2016	2.4	90
73	Prevention and Treatment of Thrombotic Antiphospholipid Syndrome <b>2017</b> , 223-233		4
72	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome <b>2017</b> , 247-266		4
71	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report <b>2017</b> , 317-338		16
70	Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 579-585	2.2	14
69	Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 526-31	2.4	104
68	Emerging Therapies in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , <b>2016</b> , 18, 22	4.9	27
67	Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 611-6	5.3	15
66	Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2680-2685	9.5	30
65	Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1432-41	9.5	183
64	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 401-14	13.6	136
63	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Population-Based Study, 1996-2011. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1078-85	4.7	98
62	Asymptomatic bacteriuria in women with autoimmune rheumatic disease: prevalence, risk factors, and clinical significance. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 868-74	11.6	6
61	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 192-200	13.6	86
60	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1011-8	2.4	369
59	A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Lupus Science and Medicine</i> , <b>2015</b> , 2, e000123	4.6	86
58	Infections and Autoimmune Renal Diseases <b>2015</b> , 929-942		1



57	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 281-91	13.6	112
56	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 685-96	13.6	248
55	Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). <i>Rheumatology</i> , <b>2014</b> , 53, 275-84	3.9	57
54	Identification and treatment of APS renal involvement. <i>Lupus</i> , <b>2014</b> , 23, 1276-8	2.6	22
53	Methodological quality of studies of end-stage renal disease risks in lupus nephritis. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, A47	5.7	78
52	Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 558-65	5.3	25
51	Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. <i>Rheumatology</i> , <b>2013</b> , 52, 448-53.9	5.9	29
50	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1771-82	2.4	692
49	Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 60-2	4.1	53
48	Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1924-30	4.3	33
47	Antiphospholipid syndrome-associated nephropathy in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 131-134	1.5	1
46	Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome <b>2012</b> , 167-179		
45	Task Force Report on Non-criteria Manifestations: Nephropathy <b>2012</b> , 207-221		1
44	Validation of new biomarkers in systemic autoimmune diseases. <i>Nature Reviews Rheumatology</i> , <b>2011</b> , 7, 708-17	8.1	29
43	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. <i>Lupus</i> , <b>2011</b> , 20, 165-73	2.6	72
42	Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. <i>Lupus</i> , <b>2011</b> , 20, 206-18	2.6	351
41	Guillain-Barre syndrome presenting with sensory disturbance following a herpes virus infection: a case report. <i>Journal of Medical Case Reports</i> , <b>2011</b> , 5, 563	1.2	3
40	Sleep disturbances in adults with arthritis: prevalence, mediators, and subgroups at greatest risk. Data from the 2007 National Health Interview Survey. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 247-60	4.7	41

39	Suicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1322-33	4.7	34
38	Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. <i>Lupus</i> , <b>2011</b> , 20, 174-81	2.6	61
37	MALT lymphoma of the lacrimal gland in the context of systemic lupus erythematosus: complete remission after treatment with rituximab. <i>Lupus</i> , <b>2010</b> , 19, 1243-5	2.6	3
36	Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2083-9	2.4	335
35	Real-time three-dimensional echocardiography in evaluating Libman-Sacks vegetations. <i>European Journal of Echocardiography</i> , <b>2010</b> , 11, 184-5		8
34	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2074-82	2.4	462
33	Presence of other autoimmune diseases in subjects with autoimmune thyroid disease. <i>American Journal of Medicine</i> , <b>2010</b> , 123, e23; author reply e25	2.4	2
32	Validity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseases. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R179	5.7	12
31	Measures of psychological distress in patients with arthritis: comment on the article by Fuller-Thomson and Shaked. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 140-1; author reply 141-2	4.7	
30	Appropriate screening for leishmaniasis before immunosuppressive treatments. <i>Emerging Infectious Diseases</i> , <b>2009</b> , 15, 1706; author reply 1706-7	10.2	7
29	Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2009</b> , 36, 131-40	12.3	74
28	Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 29-36		227
27	Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. <i>Emerging Infectious Diseases</i> , <b>2009</b> , 15, 956-9	10.2	44
26	Appropriate Screening for Leishmaniasis before Immunosuppressive Treatments. <i>Emerging Infectious Diseases</i> , <b>2009</b> , 15, 1706b-1707	10.2	0
25	Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 541-2	3.9	30
24	Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 795-7	3.9	52
23	Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1983-8	4.1	48
22	Reiter's syndrome during intravesical BCG therapy for bladder carcinoma. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 1368-9	3.9	14

21	Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. <i>American Journal of Medicine</i> , <b>2007</b> , 120, 636-42	2.4	141
20	Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 258-60	3.9	51
19	Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 2278-84		92
18	Osteoarticular Manifestations of Antiphospholipid Syndrome <b>2006</b> , 127-139		
17	Osteoarticular manifestations of antiphospholipid syndrome. <i>Rheumatic Disease Clinics of North America</i> , <b>2006</b> , 32, 523-35	2.4	7
16	Antiphospholipid syndrome nephropathy in antiphospholipid antibody-positive patients with systemic lupus erythematosus: comment on the article by Tektonidou et al. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 988-9; author reply 989-90		
15	A case with epilepsy, cognitive impairment, renal microangiopathy and high titres of anticentromere and anticardiolipin antibodies. <i>Lupus</i> , <b>2005</b> , 14, 625-8	2.6	
14	Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1159-61	2.4	80
13	Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 2569-79		168
12	Immunologic factors in the pathogenesis of osteonecrosis. <i>Orthopedic Clinics of North America</i> , <b>2004</b> , 35, 259-63, vii	3.5	27
11	Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 645-51		79
10	Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , <b>2003</b> , 48, 732-6		110
9	Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus. <i>Lupus</i> , <b>2003</b> , 12, 723-4	2.6	3
8	Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 43-8	2.4	45
7	Comparison of evidence of treatment effects in randomized and nonrandomized studies. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 286, 821-30	27.4	567
6	Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. <i>European Journal of Clinical Investigation</i> , <b>2000</b> , 30, 646-52	4.6	17
5	Microvascular abnormalities in Sjögren's syndrome: nailfold capillaroscopy. <i>Rheumatology</i> , <b>1999</b> , 38, 826-30	3.9	71
4	HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. <i>Human Immunology</i> , <b>1999</b> , 60, 1274-80	2.3	10

- 3 Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. *Journal of Clinical Immunology*, **1998**, 18, 380-91 5-7 26
- 2 Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis
- 1 Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study 1